Pembrolizumab Shows Activity Among Some Young Patients With Advanced Sarcoma
PD-1 inhibition with pembrolizumab may be an effective treatment option for adolescent and young adult patients with some sarcoma subtypes.
Diagnosis & Disease Information
Potential Clinical Benefit in Multigene Hereditary Testing for Patients With Sarcoma
There may be potential clinical benefits to performing hereditary cancer risk assessments and multi-gene panel testing in patients with sarcoma.
Talimogene Laherparepvec Plus Ipilimumab Promising for Advanced Melanoma
Talimogene laherparepvec plus ipilimumab improves the overall response rate over ipilimumab alone among patients with unresected, advanced melanoma.
In Focus: Abemaciclib for Advanced Breast Cancer
Several presentations demonstrated that abemaciclib provides clinical benefit for women with HR+/HER2-negative breast cancer who progress on or are resistant to endocrine therapy.
Future Treatment Modalities in Sarcoma: Insights From ASCO 2017
Targeted and immunotherapeutic approaches are poised to change how sarcoma will be treated in the future. Trials are being used to match tumors with appropriate treatment choices.
Overcoming Drug Resistance in the Treatment of Metastatic Breast Cancer
The management of metastatic breast cancer resistant or refractory to hormonal treatments, while still challenging, is rapidly improving.
Maintenance Pembrolizumab Does Not Improve PFS in Small-cell Lung Cancer
Maintenance pembrolizumab does not prolong progression-free survival, though it may improve overall survival, among patients with extensive-stage small-cell lung cancer.
Afatinib Not Recommended Post-CRT for Patients With Squamous Cell Carcinoma of the Head and Neck
Adding afatinib to standard CRT is not recommended for patients with primary unresected, high- or intermediate-risk HNSCC.
Momelotinib vs Ruxolitinib for Patients With Myelofibrosis
Momelotinib, an oral JAK inhibitor, is non-inferior to ruxolitinib in reducing spleen volume, though not for improving disease-related symptoms, among patients with myelofibrosis.
Aldoxorubicin: A Way Forward for Soft Tissue Sarcoma?
Although aldoxorubicin did not improve OS, the available evidence suggests that it is nevertheless superior to doxorubicin — particularly among patients with liposarcoma and leiomyosarcoma.
- Loading...
Loading...
Next post in Sarcoma
Loading... 
Loading...